Your browser is no longer supported. Please, upgrade your browser.
Settings
MYOV Myovant Sciences Ltd. daily Stock Chart
MYOV [NYSE]
Myovant Sciences Ltd.
Index- P/E- EPS (ttm)-3.37 Insider Own1.80% Shs Outstand89.11M Perf Week-10.08%
Market Cap1.68B Forward P/E- EPS next Y-1.40 Insider Trans214.66% Shs Float31.62M Perf Month4.71%
Income-289.00M PEG- EPS next Q-0.68 Inst Own35.30% Short Float9.52% Perf Quarter87.60%
Sales- P/S- EPS this Y17.70% Inst Trans0.02% Short Ratio2.25 Perf Half Y26.03%
Book/sh-1.22 P/B- EPS next Y58.90% ROA-172.50% Target Price- Perf Year108.69%
Cash/sh0.85 P/C21.11 EPS next 5Y- ROE- 52W Range4.14 - 22.07 Perf YTD16.04%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-18.38% Beta2.58
Dividend %- Quick Ratio1.00 Sales past 5Y- Gross Margin- 52W Low335.02% ATR1.29
Employees214 Current Ratio1.00 Sales Q/Q- Oper. Margin- RSI (14)49.44 Volatility5.12% 6.80%
OptionableYes Debt/Eq- EPS Q/Q32.00% Profit Margin- Rel Volume0.77 Prev Close18.70
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume1.34M Price18.01
Recom1.90 SMA20-3.74% SMA5015.58% SMA20053.86% Volume1,029,946 Change-3.69%
Feb-03-20Resumed Citigroup Neutral $25 → $15
Aug-28-19Initiated Goldman Buy
Aug-19-19Initiated SVB Leerink Outperform
May-30-19Resumed Citigroup Buy
Apr-12-19Initiated Evercore ISI Outperform
Feb-13-19Upgrade Barclays Equal Weight → Overweight $22 → $25
Oct-26-18Initiated Goldman Neutral $25
Sep-13-18Initiated JP Morgan Overweight $39
Apr-25-18Reiterated Citigroup Buy $17 → $44
Apr-05-18Downgrade Barclays Overweight → Equal Weight $18
Aug-17-17Initiated Evercore ISI Outperform $35
Nov-21-16Initiated Robert W. Baird Outperform $20
Nov-21-16Initiated JMP Securities Mkt Outperform
Nov-21-16Initiated Citigroup Buy
Nov-21-16Initiated Barclays Overweight $18
Jul-06-20 08:30AM  
Jul-05-20 09:20PM  
Jul-01-20 11:23AM  
Jun-30-20 08:30AM  
Jun-24-20 10:12AM  
09:29AM  
Jun-23-20 09:02AM  
07:30AM  
Jun-22-20 10:14PM  
04:05PM  
08:30AM  
Jun-02-20 11:44AM  
09:47AM  
09:42AM  
Jun-01-20 05:11PM  
08:00AM  
May-29-20 05:00PM  
08:09AM  
May-18-20 04:05PM  
May-14-20 08:30AM  
May-06-20 06:45PM  
May-02-20 05:56PM  
Apr-27-20 08:30AM  
Apr-26-20 05:53PM  
Apr-22-20 07:51AM  
07:50AM  
07:30AM  
Apr-21-20 05:52PM  
04:05PM  
08:30AM  
Apr-15-20 09:33AM  
Apr-14-20 08:30AM  
Apr-09-20 09:00AM  
Mar-31-20 02:00AM  
Mar-10-20 08:30AM  
Mar-09-20 08:30AM  
Feb-25-20 08:30AM  
Feb-21-20 08:31AM  
Feb-10-20 08:30AM  
08:25AM  
Feb-03-20 04:39PM  
Jan-22-20 05:00AM  
Jan-06-20 08:30AM  
Dec-30-19 08:30AM  
Dec-13-19 10:43AM  
Dec-06-19 10:59AM  
Nov-29-19 12:15PM  
08:54AM  
Nov-26-19 08:36AM  
Nov-25-19 04:05PM  
Nov-22-19 02:03PM  
Nov-20-19 09:31AM  
09:22AM  
Nov-19-19 10:19AM  
08:59AM  
08:40AM  
07:56AM  
07:30AM  
Nov-18-19 04:05PM  
Nov-12-19 08:20AM  
Nov-08-19 10:56AM  
Oct-31-19 11:50AM  
09:20AM  
Oct-21-19 08:30AM  
Oct-18-19 10:23AM  
Oct-17-19 05:00AM  
05:00AM  
Oct-16-19 07:06AM  
Oct-10-19 08:30AM  
Sep-17-19 09:20AM  
Sep-06-19 10:46AM  
07:27AM  
03:01AM  
Sep-05-19 07:10AM  
Aug-30-19 06:00AM  
Aug-27-19 10:02AM  
08:30AM  
Aug-20-19 08:30AM  
Aug-06-19 04:05PM  
Aug-05-19 06:00AM  
Jul-23-19 05:36PM  
07:30AM  
Jul-22-19 04:01PM  
Jul-16-19 10:16AM  
Jul-10-19 08:30AM  
Jul-04-19 11:01AM  
Jun-04-19 08:30AM  
May-31-19 02:31PM  
07:34AM  
May-30-19 09:01PM  
May-29-19 04:16PM  
May-24-19 04:05PM  
May-20-19 04:53PM  
May-15-19 10:49AM  
May-14-19 11:14AM  
08:10AM  
08:07AM  
07:39AM  
07:38AM  
07:30AM  
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of assisted reproduction. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was founded in 2016 and is based in London, the United Kingdom. As of December 27, 2019, Myovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Arjona Ferreira Juan CamiloChief Medical OfficerJun 24Option Exercise7.7817,446135,730162,561Jun 26 04:23 PM
Arjona Ferreira Juan CamiloChief Medical OfficerJun 24Sale20.0017,446348,920145,115Jun 26 04:23 PM
Arjona Ferreira Juan CamiloChief Medical OfficerJun 23Option Exercise7.784,05431,540149,169Jun 24 04:16 PM
Arjona Ferreira Juan CamiloChief Medical OfficerJun 23Sale20.004,05481,080145,115Jun 24 04:16 PM
Sumitomo Chemical Co., Ltd.10% OwnerMay 20Buy12.5837,897476,86248,641,181May 21 01:25 PM
Sumitomo Chemical Co., Ltd.10% OwnerMay 19Buy12.1050,000605,05048,603,284May 21 01:25 PM
Sumitomo Chemical Co., Ltd.10% OwnerMay 18Buy12.3635,000432,62548,553,284May 19 03:13 PM
Sumitomo Chemical Co., Ltd.10% OwnerMay 15Buy12.1249,812603,96648,518,284May 19 03:13 PM
Sumitomo Chemical Co., Ltd.10% OwnerMay 14Buy12.0250,000600,76048,468,472May 15 03:28 PM
Sumitomo Chemical Co., Ltd.10% OwnerMay 13Buy12.3841,331511,64148,418,472May 15 03:28 PM
Sumitomo Chemical Co., Ltd.10% OwnerMay 12Buy13.5124,448330,40548,377,141May 13 06:50 PM
Sumitomo Chemical Co., Ltd.10% OwnerMay 11Buy12.7835,000447,38448,352,693May 13 06:50 PM
Sumitomo Chemical Co., Ltd.10% OwnerMay 08Buy12.8335,000449,07548,317,693May 11 04:01 PM
Sumitomo Chemical Co., Ltd.10% OwnerMay 07Buy12.6335,000442,13848,282,693May 11 04:01 PM
Sumitomo Chemical Co., Ltd.10% OwnerMay 05Buy11.97100,0001,196,54048,247,693May 07 09:26 AM
Sumitomo Chemical Co., Ltd.10% OwnerMay 04Buy11.5050,000574,87048,147,693May 05 03:40 PM
Sumitomo Chemical Co., Ltd.10% OwnerMay 01Buy11.3850,000569,18048,097,693May 05 03:40 PM
Sumitomo Chemical Co., Ltd.10% OwnerApr 30Buy12.0850,000603,82548,047,693May 01 05:35 PM
Sumitomo Chemical Co., Ltd.10% OwnerApr 29Buy11.9250,000595,89547,997,693May 01 05:35 PM
Sumitomo Chemical Co., Ltd.10% OwnerApr 28Buy12.0550,000602,72047,947,693Apr 29 01:38 PM
Sumitomo Chemical Co., Ltd.10% OwnerApr 27Buy12.1840,503493,30247,897,693Apr 29 01:38 PM
Sumitomo Chemical Co., Ltd.10% OwnerApr 24Buy12.1543,086523,34447,857,190Apr 27 11:30 AM
Sumitomo Chemical Co., Ltd.10% OwnerApr 23Buy12.3535,000432,10347,814,104Apr 27 11:30 AM
Sumitomo Chemical Co., Ltd.10% OwnerApr 22Buy11.9350,000596,73047,779,104Apr 23 02:21 PM
Sumitomo Chemical Co., Ltd.10% OwnerApr 21Buy11.5850,200581,14047,729,104Apr 23 02:21 PM
Sumitomo Chemical Co., Ltd.10% OwnerApr 20Buy11.8250,300594,42547,678,904Apr 21 04:01 PM
Sumitomo Chemical Co., Ltd.10% OwnerApr 17Buy10.7670,000753,53647,628,604Apr 21 04:01 PM
Sumitomo Chemical Co., Ltd.10% OwnerApr 16Buy10.6470,000744,67447,558,604Apr 17 12:38 PM
Sumitomo Chemical Co., Ltd.10% OwnerApr 15Buy10.4870,000733,69847,488,604Apr 17 12:38 PM
Sumitomo Chemical Co., Ltd.10% OwnerApr 14Buy11.0070,000770,10547,418,604Apr 15 07:22 PM
Sumitomo Chemical Co., Ltd.10% OwnerApr 13Buy9.8170,000686,54647,348,604Apr 15 07:22 PM
Sumitomo Chemical Co., Ltd.10% OwnerApr 09Buy9.3770,000655,66947,278,604Apr 13 02:25 PM
Sumitomo Chemical Co., Ltd.10% OwnerApr 08Buy8.5370,000596,93947,208,604Apr 09 11:20 AM
Sumitomo Chemical Co., Ltd.10% OwnerApr 07Buy8.2170,000574,36447,138,604Apr 09 11:20 AM
Sumitomo Chemical Co., Ltd.10% OwnerApr 06Buy8.4470,000590,52047,068,604Apr 07 01:56 PM
Sumitomo Chemical Co., Ltd.10% OwnerApr 03Buy7.9370,000554,92546,998,604Apr 07 01:56 PM
Sumitomo Chemical Co., Ltd.10% OwnerApr 02Buy7.7370,000541,08646,928,604Apr 03 03:04 PM
Sumitomo Chemical Co., Ltd.10% OwnerApr 01Buy7.4670,000522,29846,858,604Apr 03 03:04 PM
Sumitomo Chemical Co., Ltd.10% OwnerMar 31Buy7.9770,000557,98446,788,604Apr 01 10:55 AM
Sumitomo Chemical Co., Ltd.10% OwnerMar 30Buy7.6570,000535,76646,718,604Apr 01 10:55 AM
Sumitomo Chemical Co., Ltd.10% OwnerMar 27Buy7.9870,000558,25046,648,604Mar 30 11:34 AM
Sumitomo Chemical Co., Ltd.10% OwnerMar 26Buy7.9470,000555,80746,578,604Mar 30 11:34 AM
Sumitomo Chemical Co., Ltd.10% OwnerMar 25Buy7.60108,100821,89546,508,604Mar 26 11:39 AM
Sumitomo Chemical Co., Ltd.10% OwnerMar 24Buy7.67211,2001,620,55946,400,504Mar 26 11:39 AM
Sumitomo Chemical Co., Ltd.10% OwnerMar 23Buy7.68211,2001,621,93246,189,304Mar 24 03:15 PM
Sumitomo Chemical Co., Ltd.10% OwnerMar 20Buy7.60193,9001,472,70945,978,104Mar 24 03:15 PM
Sumitomo Chemical Co., Ltd.10% OwnerMar 19Buy7.68193,9001,488,95845,784,204Mar 20 02:10 PM
Sumitomo Chemical Co., Ltd.10% OwnerMar 18Buy7.40193,9001,434,93845,590,304Mar 20 02:10 PM
Sablich KimChief Commercial OfficerMar 18Sale7.377855,78758,905Mar 19 04:32 PM
Sumitomo Chemical Co., Ltd.10% OwnerMar 17Buy7.40193,9001,433,94945,396,404Mar 18 04:21 PM
Sumitomo Chemical Co., Ltd.10% OwnerMar 16Buy7.25193,9001,406,00845,202,504Mar 18 04:21 PM
Sablich KimChief Commercial OfficerJan 15Sale14.044,84067,95459,690Jan 16 05:28 PM
Lang MatthewGeneral Counsel & Corp. Secy.Dec 30Sale15.5519,018295,73034,597Dec 30 07:14 PM
KARBE FRANKPrincipal Fin'l & AccountingDec 30Sale15.5519,701306,35143,324Dec 30 07:13 PM
Sablich KimChief Commercial OfficerDec 18Sale16.222,58541,92964,530Dec 19 04:25 PM
Roivant Sciences Ltd.10% OwnerDec 17Buy15.9475,0001,195,50045,008,604Dec 18 04:28 PM
Roivant Sciences Ltd.10% OwnerDec 16Buy15.13170,0002,572,20644,933,604Dec 18 04:28 PM
Roivant Sciences Ltd.10% OwnerDec 04Buy17.0675,0001,279,31544,763,604Dec 04 06:08 PM
Roivant Sciences Ltd.10% OwnerDec 02Buy18.44179,1933,305,04144,688,604Dec 04 06:08 PM
Roivant Sciences Ltd.10% OwnerNov 25Buy15.003,500,00052,500,00044,509,411Nov 27 04:45 PM
Roivant Sciences Ltd.10% OwnerNov 21Buy11.89121,9061,449,10141,009,411Nov 22 09:28 PM
Roivant Sciences Ltd.10% OwnerNov 20Buy12.90121,9061,572,58740,887,505Nov 22 09:28 PM